Cited by 2,292Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record, with a small difference in title or year; 28 of the 28 references it cites were found in a registry or an index.

C-Reactive Protein Levels and Outcomes after Statin Therapy

Open access

Ridker, Paul M, Cannon, Christopher P., Morrow, David, Rifai, Nader, Rose, Lynda M., McCabe, Carolyn H., Pfeffer, Marc A., Braunwald, Eugene·2005·New England Journal of Medicine

DOI 10.1056/nejmoa042378

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown. METHODS: We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes. RESULTS: Patients in whom statin therapy resulted in LDL cholesterol levels of less than 70 mg per deciliter (1.8 mmol per liter) had lower event rates than those with higher levels (2.7 vs. 4.0 events per 100 person-years, P=0.008). However, a virtually identical difference was observed between those who had CRP levels of less than 2 mg per liter after statin therapy and those who had higher levels (2.8 vs. 3.9 events per 100 person-years, P=0.006), an effect present at all levels of LDL cholesterol achieved. For patients with post-treatment LDL cholesterol levels of more than 70 mg per deciliter, the rates of recurrent events were 4.6 per 100 person-years among those with CRP levels of more than 2 mg per liter and 3.2 events per 100 person-years among those with CRP levels of less than 2 mg per liter; the respective rates among those with LDL cholesterol levels of less than 70 mg per deciliter were 3.1 and 2.4 events per 100 person-years (P<0.001). Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Patients who had LDL cholesterol levels of less than 70 mg per deciliter and CRP levels of less than 1 mg per liter after statin therapy had the lowest rate of recurrent events (1.9 per 100 person-years). CONCLUSIONS: Patients who have low CRP levels after statin therapy have better clinical outcomes than those with higher CRP levels, regardless of the resultant level of LDL cholesterol. Strategies to lower cardiovascular risk with statins should include monitoring CRP as well as cholesterol.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa042378

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Self-citation
C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408183310701 · Cited by 2,354
Effect of Statin Therapy on C-Reactive Protein Levels
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,644
Self-citation
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Self-citation

Flagged first, then by citations

Show all 28 references

Research works printed but not linked: 1

Davignon J, 2004, Circulation, 109, III

Sorted by citations

Items 701–800 of 1,000

The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials
Passacquale, G., Giosia, P. D., & Ferro, A. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv227 · Cited by 46
Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis?
Fougerat, A., Gayral, S., Malet, N., Briand‐Mésange, F., Breton, M., & Laffargue, M. (2009) · Clinical Science · doi:10.1042/cs20080549 · Cited by 49
Lipoproteins as Biomarkers and Therapeutic Targets in the Setting of Acute Coronary Syndrome
Rosenson, R. S., Brewer, H. B., & Rader, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.302805 · Cited by 45
Pharmacogenetic Determinants of Statin-Induced Reductions in C-Reactive Protein
Chu, A. Y., Guilianini, F., Barratt, B. J., Nyberg, F., Chasman, D. I., & Ridker, P. M. (2012) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.961847 · Cited by 45
Self-citation
Inflammageing in the cardiovascular system: mechanisms, emerging targets, and novel therapeutic strategies
Liu, D., Richardson, G. D., Benli, F. M., Park, C., de Souza, J. V. B., Bronowska, A. K., & Spyridopoulos, I. (2020) · Clinical Science · doi:10.1042/cs20191213 · Cited by 47
Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST
de Cardiología, G. D. T. P. E. D. Y. T. D. S. C. A. S. E. D. S. S. D. L. S. E. (2007) · Revista Española de Cardiología · doi:10.1157/13111518 · Cited by 46
Pueraria Mirifica Phytoestrogens Improve Dyslipidemia in Postmenopausal Women Probably by Activating Estrogen Receptor Subtypes
Okamura, S., Sawada, Y., Satoh, T., Sakamoto, H., Saito, Y., Sumino, H., Takizawa, T., Kogure, T., Chaichantipyuth, C., Higuchi, Y., et al. (2008) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.216.341 · Cited by 46
Interleukin-18 and the risk of future cardiovascular disease among initially healthy women
Everett, B. M., Bansal, S., Rifai, N., Buring, J. E., & Ridker, P. M. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.04.015 · Cited by 43
Self-citation
Increased inflammatory markers in children with familial hypercholesterolaemia
Ueland, T., Vissers, M. N., Wiegman, A., Rodenburg, J., Hutten, B. A., Gullestad, L. L., Ose, L., Rifai, N., Ridker, P. M., Kastelein, J. J. P., et al. (2006) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2006.01613.x · Cited by 45
Self-citation
Role of C-Reactive Protein in Coronary Risk Reduction: Focus on Primary Prevention
Gotto, A. M. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.10.026 · Cited by 46
Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients
Kim, J., Kang, T. S., Kim, J., Seo, H.-S., Park, S., Kim, C., Ko, Y., Choi, D., Jang, Y., & Chung, N. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.05.025 · Cited by 44
Increased endoplasmic reticulum stress and Nrf2 repression in peripheral blood mononuclear cells of patients with stable coronary artery disease
Mozzini, C., Pasini, A. F., Garbin, U., Stranieri, C., Pasini, A., Vallerio, P., & Cominacini, L. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.12.017 · Cited by 44
Proteomic analysis of endothelial cell secretome: A means of studying the pleiotropic effects of Hmg-CoA reductase inhibitors
Brioschi, M., Lento, S., Tremoli, E., & Banfi, C. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.10.003 · Cited by 44
A significant causal association between C-reactive protein levels and schizophrenia
Inoshita, M., Numata, S., Tajima, A., Kinoshita, M., Umehara, H., Nakataki, M., Ikeda, M., Maruyama, S., Yamamori, H., Kanazawa, T., et al. (2016) · Scientific Reports · doi:10.1038/srep26105 · Cited by 42
Retracted
Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice
Yokohama, K., Fukunishi, S., Ii, M., Nakamura, K., Ohama, H., Tsuchimoto, Y., Asai, A., Tsuda, Y., & Higuchi, K. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2766 · Cited by 44
Insights From Pre-Clinical and Clinical Studies on the Role of Innate Inflammation in Atherosclerosis Regression
Rahman, K., & Fisher, E. A. A. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00032 · Cited by 48
Perivascular fat attenuation index and high-risk plaque features evaluated by coronary CT angiography: relationship with serum inflammatory marker level
Dai, X. D., Deng, J., Yu, M., Lu, Z., Shen, C., & Zhang, J. (2020) · International journal of cardiac imaging · doi:10.1007/s10554-019-01758-8 · Cited by 44
Association of Common C-Reactive Protein (CRP) Gene Polymorphisms With Baseline Plasma CRP Levels and Fenofibrate Response
Shen, J., Arnett, D. K., Parnell, L. D., Peacock, J. M., Lai, C., Hixson, J. E., Tsai, M. Y., Province, M. A., Straka, R. J., & Ordovás, J. M. (2008) · Diabetes Care · doi:10.2337/dc07-1687 · Cited by 44
Inflammation, complement activation and endothelial function in stable and unstable coronary artery disease
Kostner, K., Fahti, R. B., Case, C. C., Hobson, P., Tate, J., & Marwick, T. H. (2005) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.08.028 · Cited by 44
Inflammatory markers and stroke
Elkind, M. S. V. (2008) · Current Cardiology Reports · doi:10.1007/s11886-009-0003-2 · Cited by 43
Implant Overdentures and Nutrition
Awad, M., Morais, J., Wollin, S. D., Khalil, A., Gray‐Donald, K., & Feine, J. S. (2011) · Journal of Dental Research · doi:10.1177/0022034511423396 · Cited by 44
Statin therapy of calcific aortic stenosis: hype or hope?
Liebe, V., Brueckmann, M., Borggrefe, M. M., & Kaden, J. J. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi697 · Cited by 44
CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: What Is So Bad about Reverse Epidemiology Anyway?
Kalantar‐Zadeh, K. (2007) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2007.00360.x · Cited by 43
Comparison of Clinical Outcomes of Hydrophilic and Lipophilic Statins in Patients with Acute Myocardial Infarction
Kim, M. C., Ahn, Y., Jang, S. Y., Cho, K. H., Hwang, S. H., Lee, M. G., Ko, J. S., Park, K. H., Sim, D. S., Yoon, N. S., et al. (2011) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2011.26.3.294 · Cited by 43
Recent advances in atherosclerosis-based proteomics: new biomarkers and a future perspective
Álvarez‐Llamas, G., de la Cuesta, F., Barderas, M. G., Dardé, V. M., Padial, L. R., & Vivanco, F. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.5.679 · Cited by 41
Association of statin therapy with reduced coronary plaque rupture: an optical coherence tomography study
Chia, S., Raffel, O., Takano, M., Tearney, G. J., Bouma, B. E., & Jang, I. (2008) · Coronary Artery Disease · doi:10.1097/mca.0b013e32830042a8 · Cited by 43
Statins in the treatment of polycythaemia vera and allied disorders: An antithrombotic and cytoreductive potential?
Hasselbalch, H. C., & Riley, C. H. (2006) · Leukemia Research · doi:10.1016/j.leukres.2005.12.018 · Cited by 43
State of the Art: Blood Biomarkers for Risk Stratification in Patients with Stable Ischemic Heart Disease
Omland, T., & White, H. D. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.255190 · Cited by 44
Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?
Ruscica, M., Ferri, N., Macchi, C., Corsini, A., & Sirtori, C. R. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1498118 · Cited by 43
Effects of lifestyle interventions on inflammatory markers in the metabolic syndrome
Beavers, K. M. (2010) · Frontiers in Bioscience-Scholar · doi:10.2741/s142 · Cited by 45
Is immunity a mechanism contributing to statin-induced diabetes?
Henriksbo, B. D., & Schertzer, J. D. (2015) · Adipocyte · doi:10.1080/21623945.2015.1024394 · Cited by 46
Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein?
Zimmermann, O., Bienek‐Ziolkowski, M., Wolf, B., Vetter, M., Baur, R., Mailänder, V., Hombach, V., & Torzewski, J. (2009) · Basic Research in Cardiology · doi:10.1007/s00395-009-0026-2 · Cited by 45
Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist
Voleti, B., & Agrawal, A. C. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2005.06.045 · Cited by 43
Cardiology: Post-Cardiothoracic Surgery Atrial Fibrillation: A Review of Preventive Strategies
Baker, W. L., & White, C. M. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h594 · Cited by 43
The relationship between statin use and atrial fibrillation
Patel, A., White, C. M., Shah, S. A., Dale, K. M., Kluger, J., & Coleman, C. I. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x188026 · Cited by 43
Inflammation as a Mediator of the Link between Mild to Moderate Renal Insufficiency and Endothelial Dysfunction in Essential Hypertension
Zoccali, C., Maio, R., Tripepi, G. L., Mallamaci, F., & Perticone, F. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121345 · Cited by 43
Gut Microbiota and Metabolic Syndrome: Relationships and Opportunities for New Therapeutic Strategies
Ezenabor, E. H., Adeyemi, A. A., & Adeyemı, O. S. (2024) · Scientifica · doi:10.1155/2024/4222083 · Cited by 49
A meta‐analysis of the utility of C‐reactive protein in predicting early, intermediate‐term and long term mortality and major adverse cardiac events in vascular surgical patients
Padayachee, L., Rodseth, R. N., & Biccard, B. M. (2009) · Anaesthesia · doi:10.1111/j.1365-2044.2008.05786.x · Cited by 42
Association of statins with inflammatory cytokines: A population-based Colaus study
Lyngdoh, T., Vollenweider, P., Waeber, G., & Marques-Vidal, P. M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.07.117 · Cited by 42
Comparison of Effects of Rosuvastatin and Atorvastatin on Plaque Regression in Korean Patients With Untreated Intermediate Coronary Stenosis
Hong, Y. J., Jeong, M. H., Hachinohe, D., Ahmed, K., Choi, Y. H., Cho, S. H., Hwang, S. H., Ko, J. S., Lee, M. G., Park, K. H., et al. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0658 · Cited by 41
Lovastatin-induced decrease of intracellular cholesterol level attenuates fibroblast-to-myofibroblast transition in bronchial fibroblasts derived from asthmatic patients
Michalik, M., Soczek, E., Kosińska, M., Rak, M., Wójcik‐Pszczoła, K., Lasota, S., Pierzchalska, M., Czyż, J., & Madeja, Z. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.02.023 · Cited by 42
Proteomic profiles of serum inflammatory markers accurately predict atherosclerosis in mice
Tabibiazar, R., Wagner, R. A., Deng, A. C., Tsao, P. S., & Quertermous, T. (2006) · Physiological Genomics · doi:10.1152/physiolgenomics.00240.2005 · Cited by 42
Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery disease
Konstantino, Y., Nguyen, T. T., Wolk, R. A., Aiello, R. J., Terra, S. G., & Fryburg, D. A. (2009) · Biomarkers · doi:10.1080/13547500902765140 · Cited by 42
High‐sensitivity C ‐reactive protein, low‐density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE ( Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care ) trial
Hwang, Y., Morrow, D. A., Cannon, C. P., Liu, Y., Bergenstal, R. M., Heller, S. R., Mehta, C. R., Cushman, W. C., Bakris, G. L., Zannad, F. M., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13136 · Cited by 42
Self-citation
GDF-15 (Growth Differentiation Factor 15) Is Associated With Lack of Ventricular Recovery and Mortality After Transcatheter Aortic Valve Replacement
Kim, J. B., Kobayashi, Y., Moneghetti, K. J., Brenner, D. A., O’Malley, R., Schnittger, I., Wu, J. C., Murtagh, G., Beshiri, A., Fischbein, M. P., et al. (2017) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.117.005594 · Cited by 42
A hook effect-free immunochromatographic assay (HEF-ICA) for measuring the C-reactive protein concentration in one drop of human serum
Oh, J., Joung, H., Han, H. S., Kim, J. K., & Kim, M. (2018) · Theranostics · doi:10.7150/thno.24034 · Cited by 43
The Role of Colchicine in Acute Coronary Syndromes
Vaidya, K., Martínez, G., & Patel, S. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.07.023 · Cited by 42
Therapeutic Lowering of C-Reactive Protein
Jimenez, R. V., & Szalai, A. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.619564 · Cited by 42
The Relationship Between Obesity and Atherosclerotic Progression and Prognosis Among Patients With Coronary Artery Bypass Grafts
Wee, C. C., Girotra, S. R., Weinstein, A. R., Mittleman, M. A., & Mukamal, K. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.05.021 · Cited by 42
Prospective evaluation of the relationship between C-reactive protein, D-dimer and progression of peripheral arterial disease
Musicant, S. E., Taylor, L. M., Peters, D., Schuff, R. A., Urankar, R. N., Landry, G. J., & Moneta, G. L. (2006) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2005.12.051 · Cited by 42
Traditional and Emerging Risk Factors for Cardiovascular Disease
Eaton, C. B. (2005) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2005.09.009 · Cited by 43
The Effect of Statins on Mortality in Septic Patients: A Meta-Analysis of Randomized Controlled Trials
Pasin, L., Landoni, G., Castro, M. L., Cabrini, L., Belletti, A., Feltracco, P., Finco, G., Carozzo, A., Chiesa, R., & Zangrillo, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082775 · Cited by 41
The relationship between five different measures of structural social capital, medical examination outcomes, and mortality
Muennig, P. A., Cohen, A. K., Palmer, A., & Zhu, W. (2013) · Social Science & Medicine · doi:10.1016/j.socscimed.2013.02.007 · Cited by 43
Neutrophil to platelet ratio: A novel prognostic biomarker in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention
Somaschini, A., Cornara, S., Demarchi, A., Mirizzi, A. M., Fortuni, F., Crimi, G., Ferlini, M., Camporotondo, R., Gnecchi, M., Visconti, L. O., et al. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319894103 · Cited by 41
Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography
Gao, F., Wang, Z. J., Ma, X., Shen, H., Yang, L., & Zhou, Y. J. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01528-3 · Cited by 41
Levels of acute phase proteins remain stable after ischemic stroke
Elkind, M. S. V., Coates, K., Tai, W., Paik, M. C., Boden-Albala, B. M., & Sacco, R. L. (2006) · BMC Neurology · doi:10.1186/1471-2377-6-37 · Cited by 41
Genetic determinants of C-reactive protein
Danik, J. S., & Ridker, P. M. (2007) · Current Atherosclerosis Reports · doi:10.1007/s11883-007-0019-2 · Cited by 42
Self-citation
Tomato-rich (Mediterranean) diet does not modify inflammatory markers
Blum, A., Merei, M., Khazim, K., Peleg, A., & Blum, N. (2007) · Clinical and investigative medicine · doi:10.25011/cim.v30i2.982 · Cited by 41
Predicting cardiovascular events with coronary calcium scoring
Weintraub, W. S., & Diamond, G. A. (2008) · New England Journal of Medicine · doi:10.1056/nejme0800676 · Cited by 40
High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial
Nishikido, T., Oyama, J., Keida, T., Ohira, H., & Node, K. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.05.017 · Cited by 40
A role for monomeric C-reactive protein in regulation of angiogenesis, endothelial cell inflammation and thrombus formation in cardiovascular/cerebrovascular disease?
SLEVIN, M. A., & Krupiński, J. (2009) · PubMed · doi:10.14670/hh-24.1473 · Cited by 40
Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: a longitudinal study
Guasti, L., Marino, F., Cosentino, M., Cimpanelli, M., Maio, R. C., Klersy, C., Crespi, C., Restelli, D., Simoni, C., Franzetti, I., et al. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000251903.62804.77 · Cited by 40
Statins: protectors or pretenders in prostate cancer?
Moon, H., Hill, M. M. C., Roberts, M. J., Gardiner, R. A., & Brown, A. J. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.12.007 · Cited by 41
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Storey, B. C., Staplin, N., Haynes, R., Reith, C. A., Emberson, J., Herrington, W. G., Wheeler, D. C., Walker, R. J., Fellström, B., Wanner, C., et al. (2017) · Kidney International · doi:10.1016/j.kint.2017.09.011 · Cited by 43
NHG-Standaard Cardiovasculair risicomanagement
Wiersma, T., Boukes, F., Geijer, R. M. M., & Goudswaard, A. N. (2009) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-6614-9_6 · Cited by 40
The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers
Efrati, S., Averbukh, M., Dishy, V., Faygenzo, M., Friedensohn, L., & Golik, A. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0238-4 · Cited by 40
The effect of weight loss after gastric bypass on C-reactive protein levels
Zagorski, S. M., Papa, N., & Chung, M. H. (2005) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2005.01.001 · Cited by 41
Reduction of C-reactive protein and the use of anti-hypertensives.
Savoia, C., & Schiffrin, E. L. (2007) · PubMed Central · Cited by 40
High serum high-sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome
Aso, Y., Wakabayashi, S., Nakano, T., Yamamoto, R., Takebayashi, K., & Inukai, T. (2006) · Metabolism · doi:10.1016/j.metabol.2006.03.011 · Cited by 40
C-reactive protein (CRP): more than just an innocent bystander?
Paraskevas, K. I., & Mikhailidis, D. P. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253654 · Cited by 40
Statin Therapy in the Reduction of Cardiovascular Events in Patients Undergoing Intermediate‐Risk Noncardiac, Nonvascular Surgery
Raju, M. G., Pachika, A., Punnam, S. R., Gardiner, J. C., Shishehbor, M. H., Kapadia, S. R., & Abela, G. S. (2013) · Clinical Cardiology · doi:10.1002/clc.22135 · Cited by 39
On-Statin Cholesteryl Ester Transfer Protein Mass and Risk of Recurrent Coronary Events (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 [PROVE IT-TIMI 22] Study)
Khera, A. V., Wolfe, M. L., Cannon, C. P., Qin, J., & Rader, D. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.03.057 · Cited by 38
Self-citation
Relationship of Helicobacter pylori Infection to Arterial Stiffness in Japanese Subjects
Saijo, Y., Utsugi, M. T., Yoshioka, E., Horikawa, N., Sato, T., Gong, Y., & Kishi, R. (2005) · Hypertension Research · doi:10.1291/hypres.28.283 · Cited by 39
Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes
Rosenson, R. S. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833eb581 · Cited by 39
Rosuvastatin: efficacy, safety and clinical effectiveness
Soran, H., & Durrington, P. N. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.12.2145 · Cited by 39
Relationship Between Serum Inflammatory Marker Levels and the Dynamic Changes in Coronary Plaque Characteristics After Statin Therapy
Kwon, O., Kang, S., Kang, S. H., Lee, P. H., Yun, S., Ahn, J., Park, D., Lee, S., Kim, Y., Lee, C. W., et al. (2017) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.116.005934 · Cited by 39
Causes and consequences of inflammation on anemia management in hemodialysis patients
Chawla, L. S., & Krishnan, M. (2009) · Hemodialysis International · doi:10.1111/j.1542-4758.2009.00352.x · Cited by 38
Metabolic depression in hibernation and major depression: An explanatory theory and an animal model of depression
Tsiouris, J. A. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2005.05.044 · Cited by 42
The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis
Yu, M., Tsai, S., & Kuo, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061260 · Cited by 39
Ezetimibe in Renal Transplant Patients with Hyperlipidemia Resistant to HMG-CoA Reductase Inhibitors
Langone, A. J., & Chuang, P. (2006) · Transplantation · doi:10.1097/01.tp.0000203167.77570.11 · Cited by 39
Anti-inflammatory drugs and atherosclerosis
Moubayed, S. P., Heinonen, T. M., & Tardif, J. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282f0ee11 · Cited by 38
Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta
Brili, S. V., Tousoulis, D., Antonopoulos, A. S., Antoniades, C. A., Hatzis, G., Bakogiannis, C., Παπαγεωργίου, Ν., & Stefanadis, C. (2011) · Heart · doi:10.1136/heartjnl-2011-300287 · Cited by 38
Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer
Wei, T.-T., Lin, Y., Chen, W., Luo, P., Lin, Y., Shun, C., Lin, Y.-H., Chen, J.-B., Chen, N.-W., Fang, J., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.07.019 · Cited by 39
Mediterranean-type diets and inflammatory markers in patients with coronary heart disease: a systematic review and meta-analysis
Mayr, H. L., Tierney, A. C., Thomas, C. J., Ruiz‐Canela, M., Radcliffe, J., & Itsiopoulos, C. (2017) · Nutrition Research · doi:10.1016/j.nutres.2017.10.014 · Cited by 38
Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection
Daiber, A., Steven, S., Euler, G., & Schulz, R. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210125155821 · Cited by 40
C-reactive protein and the risk of developing type 2 diabetes in Aboriginal Australians
Wang, Z., & Hoy, W. E. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.07.018 · Cited by 38
Correlation of High Sensitivity C-Reactive Protein and Calcific Aortic Valve Disease
Jeevanantham, V., Singh, N., Izuora, K. E., D'Souza, J. P., & Hsi, D. H. (2007) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60994-4 · Cited by 38
Association between anxiety and C-reactive protein levels in stable coronary heart disease patients
Bankier, B., Barajas, J., Martinez-Rumayor, A., & Januzzi, J. L. (2009) · Psychosomatics · doi:10.1176/appi.psy.50.4.347 · Cited by 37
The Role of C-reactive Protein in Patient Risk Stratification and Treatment
Arroyo‐Espliguero, R., Viana-Llamas, M. C., Silva, J. A., & y, P. A. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.49 · Cited by 41
Association between major depressive disorder and C-reactive protein levels in stable coronary heart disease patients
Bankier, B., Barajas, J. A., Martinez‐Rumayor, A., & Januzzi, J. L. (2008) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2008.09.010 · Cited by 37
Inhibiting C-Reactive Protein for the Treatment of Cardiovascular Disease: Promising Evidence from Rodent Models
Szalai, A. J., McCrory, M. A., Xing, D., Hage, F. G., Miller, A. C., Oparil, S., Chen, Y.-F., Mazzone, M., EARLY, R. J., Henry, S. P., et al. (2014) · Mediators of Inflammation · doi:10.1155/2014/353614 · Cited by 37
The Statin–Iron Nexus: Anti-Inflammatory Intervention for Arterial Disease Prevention
Zacharski, L. R., DePalma, R. G., Shamayeva, G., & Chow, B. K. (2013) · American Journal of Public Health · doi:10.2105/ajph.2012.301163 · Cited by 36
Inflammation and coagulation in atherosclerosis
Krychtiuk, K. A., Kastl, S., Wojta, J., & Speidl, W. S. (2013) · Hämostaseologie · doi:10.5482/hamo-13-07-0039 · Cited by 37
The cytokine milieu of diabetic wounds
DeClue, C. E., & Shornick, L. P. (2015) · Diabetes Management · doi:10.2217/dmt.15.44 · Cited by 38
Statins in the treatment of COPD and asthma — where do we stand?
So, J. Y., Dhungana, S. K., Beros, J., & Criner, G. J. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.01.001 · Cited by 37
The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event
Munkhaugen, J., Otterstad, J. E., Dammen, T., Gjertsen, E., Moum, T., Husebye, E., & Gullestad, L. L. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318768940 · Cited by 39
The role of splanchnic congestion and the intestinal microenvironment in the pathogenesis of advanced heart failure
Polsinelli, V. B., Marteau, L., & Shah, S. J. (2019) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000414 · Cited by 37
Atherothrombosis and the NLRP3 inflammasome – endogenous mechanisms of inhibition
Satish, M., & Agrawal, D. K. (2019) · Translational research · doi:10.1016/j.trsl.2019.08.003 · Cited by 39
Precision Multiparameter Tracking of Inflammation on Timescales of Hours to Years Using Serial Dried Blood Spots
Anderson, L., Razavi, M., Pope, M. E., Yip, R., Cameron, L. C., Bassini, A., & Pearson, T. W. (2020) · Bioanalysis · doi:10.4155/bio-2019-0278 · Cited by 37
Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome
Liu, H., Guo, Y., Zhu, C., Wu, N., Gao, Y., Xu, R., Dong, Q., Qian, J., Dou, K., & Li, J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03448-x · Cited by 37

Authors: Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Ridker, Paul M
Cannon, Christopher P.
Morrow, David
Rifai, Nader
Rose, Lynda M.
Pfeffer, Marc A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2005-01-06
Volume: 352
Issue: 1
Pages: 20-28
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa042378
OpenAlex: W2118154631
Cited by: 2,292
References: 28
Citations by year: 2026: 32 · 2025: 46 · 2024: 47 · 2023: 52 · 2022: 70 · 2021: 58 · 2020: 74 · 2019: 64 · 2018: 72 · 2017: 54 · 2016: 78 · 2015: 62 · 2014: 67 · 2013: 93 · 2012: 88
FWCI: 282.76
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: C-reactive protein, statin therapy, LDL cholesterol, atorvastatin, pravastatin, acute coronary syndrome, reinfarction, coronary death, cardiovascular risk, lipid-lowering targets
MeSH terms: Atorvastatin, Gatifloxacin, Anticholesteremic Agents, C-Reactive Protein, Coronary Disease, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Pyrroles, Risk Factors, Biomarkers, Incidence, Proportional Hazards Models, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Fluoroquinolones, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

C-Reactive Protein Levels and Outcomes after Statin Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks